HelomicsTM to Present at the Personalized Medicine World Conference

Personalized Medicine World Conference

PITTSBURGH--()--Helomics Corporation, a privately-held comprehensive personalized healthcare company that develops proprietary innovative next generation diagnostics for the oncology field, announced today that the Company is scheduled to present at the Personalized Medicine World Conference taking place in Mountain View, CA on January 26-28, 2015.

Neil Campbell, President and Chief Executive Officer of Helomics, will provide an overview of the personalized healthcare landscape, the Company’s business and it’s comprehensive tumor profiling technologies during his live presentation and will be available to participate in one-on-one meetings.

               

Event:

Personalized Medicine World Conference

Date:

Tuesday, January 27, 2015

Time:

11:30am (Pacific Time), Track 3

Location:

Computer History Museum, Mountain View, CA
 

About Personalized Medicine World Congress
The Personalized Medicine World Conference (PMWC) is an independent and established conference that attracts globally recognized authorities and experts across healthcare and biotechnology sectors. The Conference showcases practical content and disease pathways that help close the knowledge gap between different sectors, thereby catalyzing cross-functional collaboration to further adoption of personalized medicine in the clinic. For more information please visit: http://pmwcintl.com/index.php.

About Helomics™ Corporation
Helomics is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a comprehensive personalized tumor profile utilizing a proprietary set of laboratory platforms that leverage both live and fixed cellular analysis to allow physicians to personally characterize malignant tumors. Helomics’ novel molecular and cellular markers and bioinformatics services are designed to support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.

Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains two CLIA-certified laboratories. For more information please visit: www.helomics.com.

Contacts

Tiberend Strategic Advisors, Inc. for Helomics
Investors
Joshua Drumm, Ph.D., 212-375-2664
jdrumm@tiberend.com
or
Media
Claire Sojda, 212-375-2686
csojda@tiberend.com

Contacts

Tiberend Strategic Advisors, Inc. for Helomics
Investors
Joshua Drumm, Ph.D., 212-375-2664
jdrumm@tiberend.com
or
Media
Claire Sojda, 212-375-2686
csojda@tiberend.com